The effects of inflammatory substances, bradykinin (BK), 5-HT, and histamine (HIS), on the release of calcitonin generelated peptide (CGRP) from the peripheral terminals of sensory afferents in the rat trachea were examined ex viva. With intralumenal perfusion, the isolated rat trachea displays low but measurable secretion of CGRP (32 + 4.6 fmol/lO min fraction). The addition of BK (1O-B to lo-' M) to the superfusate resulted in an immediate, concentration-dependent increase in the level of CGRP (5-30-fold increase above baseline)
in the perfusates, and this effect showed a concentration-dependent tachyphylaxis.
[Des-Arg'O]-kallidin, a B, receptor agonist, at concentrations of up to lo-' M did not induce any significant increase in CGRP outflow from the rat trachea. HIS at 1 O-4 M caused a modest but progressive augmentation in the release of CGRP. 5-HT at lOma M had no effect upon the resting efflux of CGRP, but at a concentration of 10 m(L M significantly enhanced the release of CGRP evoked by capsaicin (lOme M). Similar conditioning studies carried out with HIS and BK showed no augmentation. BK-evoked CGRP efflux was significantly inhibited by Hyp5, This~a, antagonist) and indomethacin.
While [Des-Args, Leu*]-BK (B, antagonist) also caused a reduction of BK-induced release, its effect did not reach statistical significance. The facilitatory effect of 5-HT on capsaicin-evoked release was not markedly affected by 5-HT, or 5-HT, antagonists, (s)-(-)propranolol or methysergide, but was totally abolished by the 5-HT, receptor antagonist ICS 205-930 and also by indomethacin.
These data suggest that BK, acting through a B, receptor, activates CGRP release from the peripheral terminals of capsaicin-sensitive sensory afferents. The sensitizing effect of 5-HT on the capsaicin-evoked release of CGRP may be mediated via a 5-HT, receptor.
Both actions appear to require the formation of cyclooxygenase products for their manifestation. [Key words: bradykinin, 5-HT, histamine, capsaicin, calcitonin gene-related peptide, release, trachea]
The peripheral terminals of unmyelinated sensory axons are widely distributed. Activation of these terminals is known to influence blood flow, capillary permeability, and local inflam-matory cell function (see Szolcsanyi, 1984) . The effects are thought to be mediated by the local release of mediators such as the tachykinins and calcitonin gene-related peptide (CGRP) (see Holzer, 1988) . The mammalian respiratory tract, including the trachea, is innervated by unmyelinated afferents containing CGRP and, to a lesser extent, substance P and neurokinin A Cadieux et al., 1986) . Thus, manipulations that evoke neurogenic inflammatory responses observed in the trachea, for example, an increase in vascular permeability by local application of capsaicin (CAP) or an increase in tracheal blood flow by antidromically electrical stimulation of vagal nerve (see Martling, 1987) , may do so by the local release of these peptides. In previous work, using the intralumenally perfused isolated trachea, we have shown that CAP, excess potassium, or electrical field stimulation will yield an acute stimulus-dependent increase in the extracellular levels of CGRP (Hua and Yaksh, 1992) . This release is calcium dependent and can be induced by the local excitation of the TTX-treated axon (Hua and Yaksh, 1991) , emphasizing that CGRP and tachykinin activity is released from these tracheal afferents by local terminal depolarization.
It has been shown that local application of a variety of materials typically found in the tissue following local injury can evoke activity in C-fibers. Thus, mast cell degranulation leads to the release of histamine (HIS) and 5-HT as well as other inflammatory mediators (Fewtrell et al., 1982; Schleimer et al., 1986) . Activation of the Hageman factor and the initiation of certain Hageman-dependent pathways lead to the formation of BK (Miller and Margolius, 1988) . These agents have been shown to evoke sensory C-fiber excitation (Kaufman et al., 1980; Lang et al., 1990) . Electrophysiological study of the rat skin has revealed that 5-HT excited 43% of the polymodal C-fibers that are also driven by BK and CAP. Furthermore, conditioning treatment with 5-HT caused a sensitization to subsequent BK stimulation (Lang et al., 1990) .
Given the correlation outlined above between terminal activity and local release, it follows that pharmacological stimuli known to activate C-fiber terminals may result in the local release of terminal contents. The current thinking regarding the release of CGRP from the afferent terminal suggests that stimuli that lead to the activation of the C-fiber terminal will in fact evoke the exocytotic release of the vesicular contents of the terminal. Thus, studies carried out in guinea pig lung (Saria et al., 1988) or heart (France-Cereceda et al., 1989; Geppetti et al., 1991) have shown that, consistent with the stimulatory effect, local application of BK will evoke the subsequent release ofthe peptides from the peripheral terminals. This measurement of peripheral afferent release thus provides a direct method for
k loo 8 50 0 1 2 3 4 5 6 7 8 91011 FRACTION Figure I . CGRP level (femtomoles per 10 min sample) in the per& ates from intralumenally perfused rat trachea. BK (10m6 to 1O-4 M) was applied in fractions 4 and 9. Each value represents the mean + SEM of four or five experiments. *, P < 0.05 as comparedfraction 3 versus 4, 8 versus 9, and 4 versus 9, by using one-way ANOVA for repeated measurements followed by Dunnett's test.
assessing the local pharmacology of the peripheral terminal. Given the well-defined release of CGRP from C-fibers in the trachea and the known stimulatory effects of several autocoids on vagal afferents, we sought, in the present study, to examine the effects of three inflammatory substances, BK, HIS, and 5-HT, on tracheal afferent CGRP release and to define the receptor pharmacology of their actions. 
Materials and Methods
Release experiment. Male Sprague-Dawley rats (300-350 gm body weight) were used in the present study. The animals were anesthetized with sodium pentobarbital (Anthony Prod; 50 mg/kg, i.p.) and decapitated. The trachea (from larynx to carina) was carefully removed and placed in a perfusion bath (37°C). Intralumenal tracheal perfusion was carried out with oxygenated (95% O,, 5% CO,) Krebs'-bicarbonate solution, which contained (in mM) NaCl, 118.3; KCl, 4.7; CaCl,, 2.5; MgSO,, 1.2; NaHCO,, 25; KH,PO,, 1.2; and, glucose, 11; 0.3% bacitracin added to prevent possible peptide degradation; pH 7.35-7.45. The perfusion flow rate was 0.2 mUmin. After a 30 min equilibration period, perfusates (2 ml) were collected at 10 min intervals in test tubes containing acetic acid (final concentration of 2 M). To investigate the possible facilitatory effects on CGRP release, BK, 5-HT, and HIS (all given at a concentration of 1O-6 M) were added to the perfusate in the sample preceding and during the administration of CAP ( 1O-6 M). To study the antagonist pharmacology of the effects of two BK analogs, [D-A@, Hyp3, Thi5,8, o-Phe7]-BK(B,) (Dray and Perkins, 1988) or [DesArg9, Leu8]-BK (B,) (Regoli et al., 1990) , (1O-6 or 5 x 1O-6 M) was applied in the sample 10 min before and during the application of BK. For 5-HT, the 5-HT antagonists (s)-(-)propranolol (5-HT,) (Hide et al., 1989) , methysergide (5-HT,) (Fozard, 1984) , and.ICS 265-930 (5-HT,) (Eschalier et al.. 1989 ) (1O-6 M) were similarlv aDDlied 10 min before-and during the'administration of 5-HT. To cdnsihkr the role of cyclooxygenase products, indomethacin (1O-5 M) was applied 20 min before and during BK or 5-HT application. To examine the effects of capsaicin desensitization, CAP ( 1O-5 M) was applied in samples 2-4 and BK was then applied in sample 5 (see Fig. 2 ). All fractions were then frozen and lyophilized before radioimmunoassay (RIA).
Radioimmunoassay. CGRP determination was achieved with RIA using CGRP antibody G987 (1:84,000) and 12+Ty?-CGRP tracer. CGRP antibody G987 is a gift from Dr. H. Heath (Mayo Clinic, MN), and details of the antibody have been reported (Cater et al., 1991) . The absolute sensitivity of G987 is 4.0 fmol/assay tube, CGRP antibody G987 is 100% cross-reactive to rat CGRP, human CGRP-LU, and human CGRP-& but does not cross-react to calcitonin, CGRP,,,,, CGRP,,,,, or SP (< 1% at 1 pmol/tube). In a previous study, we have demonstrated that the immunoreactivity released from the rat trachea detected by antibody G987 was eluted as a single peak at the same fraction as svnthetic rat CGRP-B fHua and Yaksh. 1992). CGRP trace was nurified by elution from a reverse-phase column usingHPLC with an aceionitrile gradient. The assay was carried out in duplicate, and nonspecific binding and blanks were assessed. The peptide levels are expressed as femtomoles per 10 min fraction. The background blanks were examined in normal Krebs' buffer or buffer containing the substances examined, neither of them interfered with CGRP RIA.
Drugs. We used bradykinin acetate salt (Sigma), 5-hydroxytryptamine hydrochloride initially dissolved in ethanol and subsequently diluted in Krebs' buffer with a final concentration of 0.6-1.0% ethanol. In previous work, we have shown that this vehicle did not influence the basal release of CGRP (Hua and Yaksh, 1992) . The other agents were all dissolved in Krebs' buffer. All agents were reagent grade. Data analysis. Statistical significance was calculated using one-way analysis of variance (ANOVA), with multiple comparisons for independent or repeated measurements followed by Dunnett's test. Critical values reaching a P < 0.05 level were considered significant.
Results
Basal release of CGRP In the perfusate from the isolated rat trachea, basal outflow of CGRP was 32 + 5 fmol per 10 min fraction in untreated preparation (n = 30) (Figs. 14) . In the absence of pharmacological manipulation, this level remained stable for periods in excess of 1.5 hr.
Evoked release of CGRP Exposure of the rat trachea to BK-containing ( 1O-6 to 10m4 M) buffer resulted in a concentration-dependent increase of CGRP level in the perfusates (Fig. 1) . Forty minutes after the first application with BK at 1O-5 M, a second exposure to BK at the same concentration caused a similar amount of release of CGRP (Fig. 1) . The release evoked by a second application of BK at 10m4 M, however, was significantly diminished as compared to the first exposure [F(4,50) = 5.12, p < 0.011 (Fig. 1). [DesArglO]-kallidin, a B, agonist (Regoli et al., 1990) was without effect at 1O-6 M and 10m5 M (data not shown). A modest numerical increase in CGRP was seen at 1O-4 M (basal, 33 + 5.7 fmol; [Des-ArglO]-kallidin, 45 -t 9.9 fmol per 10 min fraction; n = 6) but this change did not achieve statistical significance. Continued application of CAP at 10m5 M for 30 min evoked an acute release followed by a progressive decline in the subsequent samples to baseline. The subsequent application of BK at 1O-5 M was then without effect (Fig. 2) . 5-HT at 1O-4 M (Fig. 3 ) and HIS at 1O-5 M (data not shown) did not cause any change in the efflux of CGRP. HIS at 1O-4 M induced a modest, gradual increase in CGRP outflow. Following the second application of HIS, there was a pronounced increase in release [F(3,32) = 6.5, p < O.OOl] at the same concentration (Fig. 3) .
The addition of a CAP-containing buffer (1 Om6 M) induced a remarkable efflux of CGRP from the perfused rat trachea (ACGRP = 204 f 48 fmol, basal level of the release subtracted) (Fig. 4) . Conditioning application of 5-HT, at a concentration (1 Om6 M) that had no effect upon basal release, served to augment prominently the release evoked in the presence of CAP (ACGRP = 405 f 53 fmol) [F(3,29) = 2.88, p < 0.051 (Fig. 4) . CAPinduced peptide release was not altered in the presence of BK or HIS (Fig. 4) .
Bradykinin antagonists [Des-Arg9, Leu*]-BK and [D-Argo, Hypl, Thi5.*, D-Phe']-BK, both at 1O-6 M, had no effect upon the release evoked by BK (5 x 1O-6 M) (Fig. 5) . (Fig. 6 ).
Discussion
In the present study, CGRP levels in the perfusates from isolated rat trachea were elevated by BK and the CAP-evoked release was augmented by 5-HT. Previous studies have shown that CGRP is contained in vagal afferent C-fibers and these stores have been shown to be CAP sensitive (Cadieux et al., 1986) . Immunohistochemical studies have demonstrated that, in addition to primary sensory nerve fibers, modest amounts of CGRP immunoreactivity exist in endocrine-like cells in the epithelium of the rat trachea (Shimosegawa and Said, 1991) . We do not believe these cells contribute to the present evoked release because (1) these cells appear to be CAP resistant (Shimosegawa and Said, 199 l) , and (2) the preliminary result has shown that tracheal CGRP release still exists after stripping of the epithelium (M. Hogman and X.-Y. Hua, unpublished observations). These observations and the observation from the present study that BK did not induce any release in the CAP-desensitized trachea thus suggest that the peptide response to these inflammatory agents reflects an action on the afferent terminal, which is ultimately reflected in the release of CGRP. The issues relevant to the several autocoids will be considered below.
Bradykinin
In the present study, we observed that local application of BK to the inner lumen of the rat trachea induced a concentration- (CONT, control) . ACGRP: the evoked release in femtomoles per 10 min collection, with the baseline of the release subtracted. **, P < 0.01, control group versus ICS 205-930; *, P < 0.05, control group versus indomethacin group; one-way ANOVA for independent groups followed by Dunnett's test. The data are given as mean + SEM and represent observations from 7-l 2 experiments. dependent release of CGRP, which was indomethacin sensitive. This result is consistent with previous work indicating that many of the actions of BK on smooth muscle and in activating the peripheral terminal of primary sensory neurons are mediated by the release of prostaglandins (PGs) (see Regoli et al., 1990) . Importantly, BK will in fact stimulate PGE, release from human (Churchill et al., 1989) and canine tracheal epithelial cells (Leikauf et al., 1985) , PGI, from the guinea pig heart (Geppetti et al., 199 1) , and cultured endothelial cells from the bovine aorta (Hock et al., 199 1) . In the airway, PGE,, PGE,, and PGF,, have been found to activate afferent C-fibers (Coleridge et al., 1976) and to facilitate vascular permeability induced by CAP (Saria and Lundberg, 1984) . In other work, we have found that PGE,, PGE,, PGF,,, and PGI, are all able to induce CGRP release from the CAP-sensitive afferent in the rat trachea, and this release is not altered by pretreatment with indomethacin (X.-Y. Hua et al., unpublished observations) . The observation that repeated application of BK resulted in a subsequent diminution of the amount of CGRP released, with the degree of reduction proportional to the first exposure concentration, is consistent with other studies with this peptide. Thus, in rat saphenous nerve preparation, half of the BK-sensitive C-fibers did not respond to a second BK stimulus. This desensitization could not be reversed by the application of lOOfold higher BK concentration or by a 1.5-hr washout period (Lang et al., 1990) . The mechanism of this inactivation is not clear. However, McGehee and colleagues in their recent study (McGehee et al., 1992) have provided evidence suggesting that the nitric oxide-cyclic GMP pathway is involved in BK desensitization in rat dorsal root ganglion cells.
With regard to the pharmacology of the BK effect, BK and related kinins exert their biological effects by activating at least two different receptor types: B, and B, (see Regoli et al., 1990) . The BK receptor mediating the nociceptor response to BK is believed to have the pharmacological characteristics of the B, subtype (Dray and Perkins, 1988; Mizumura et al., 1990 ). Furthermore, electrophysiological studies have provided evidence that a B,-preferring agonist was unable to evoke activity in nociceptors (Mizumura et al., 1990) . Moreover, the B,, but not B,, antagonist displayed an inhibitory effect on nociceptive responses to BK (Dray and Perkins, 1988) . In the present study, two specific observations were made. First This value is essentially identical to the pA, value obtained in guinea pig taenia caeci (PA, is about 5.5) (Field et al., 1988) and in guinea pig ileum (PA, = 6.0) (Steranka et al., 1989) . This agent does, however, appear to be more potent in the rat uterus (PA, = 6.9) (Steranka et al., 1989) .  which is known to have a relatively low affinity for the B, receptor (pD, < 5.0), displayed a potent antagonistic effect on the rabbit aorta: a pure B, receptor system (PA, = 7.27) (see Regoli et al., 1990) . It has been reported that prostanoid synthesis activated by BK may also be mediated via a B, receptor (Hock et al., 1991; Neppl et al., 1991) . Based on antagonist analysis, in the guinea pig trachea, BK-induced, PG-dependent relaxation appeared not to involve activation of either a B, or B, site (Rhaleb et al., 1988) . A possible species difference, consistent with other BK receptor types, must be considered (Regoli et al., 1990) .
Autoradiographic studies have revealed BK binding sites to be found in small dorsal root ganglion cells, and in high concentrations in regions of the dorsal horn to which primary afferents project and in the periphery (Steranka et al., 1988) . While these binding data suggest that the BK sites may be on the central and peripheral terminals of CAP-sensitive primary afferents, it is not clear that CGRP released by BK is via a receptor located on the terminal. The certainty of a direct effect is called into question by observations that (1) the BK effect is mediated through the release of PGs (see above), and (2) sympathetic neurons may be involved in BK-induced hyperalgesia and inflammation (Levine et al., 1986; Taiwo and Levine, 1988; Lee et al., 1991) .
Histamine and S-HT HIS and 5-HT have been reported to be able to excite certain limited populations of polymodal C-fiber afferents (see Handwerker, 1990) . 5-HT-and HIS-evoked increases in vascular permeability in the airway are absent in the animal pretreated with CAP suggesting a possible stimulatory effect upon the C-fiber terminal. In the present study, however, 5-HT did not exert any direct excitatory effect on CGRP release, and HIS displayed some modest activity at high concentrations. The modest action might emphasize that HIS and 5-HT are rapidly taken up and metabolized or that they interact with axons that do not secrete CGRP. As will be noted below for 5-HT, this does not appear to be the case.
5-HT receptor
Previous studies have emphasized that the action of 5-HT on the peripheral terminal of primary sensory afferents is mediated by a receptor having characteristics resembling those of a 5-HT, receptor (Higashi and Nishi, 1982; Round and Wallis, 1985; Eschalier et al., 1989) . For example, 5-HT evokes depolarization of primary afferents in rabbit nodose ganglion that is blocked in a competitive fashion by ICS 205-930 (Round and Wallis, 1985) but not by methysergide (Higashi and Nishi, 1982) . Both 5-HT and 5-HT, agonist 2-methyl-5-HT caused a painful effect when applied to a blister base of human forearm. ICS 205-930 in the nanomolar range blocked both 5-HT-evoked and 5-HTpotentiated nociceptive effects by BK in human blister (Richardson et al., 1985) . ICS 205-930 also blocked carrageenaninduced hyperalgesia in rats (Eschalier et al., 1989) , which also suggests the endogenous release of 5-HT as well as its involvement in the sensitization of peripheral nociceptors and the role of the 5-HT, receptor. Comparable results were observed in the present study. Thus, among the 5-HT antagonists examined, only ICS 205-930 (5-HT, antagonist), and not (s)-(-)propran-0101 or methysergide (5-HT, and/or 5-HT, antagonists), blocked the facilitatory effect of 5-HT on the CAP-evoked release of CGRP from the trachea. A putative 5-HT, receptor has been recently proposed (Dumuis et al., 1988; Clarke et al., 1989) , on which ICS 205-930 in the micromolar range is reported to function as an antagonist (Villalon et al., 1990 (Villalon et al., , 1991 . Thus, we should not exclude the possibility of either or both a 5-HT, and a 5-HT, receptor in the trachea.
Aferent terminal sensitization Both BK and 5-HT are also well known for their ability to sensitize the nociceptor (Lang et al., 1990; see Basbaum, 199 1) . This facilitation of BK, however, has been proposed by an action on an intermediate system, such as the sympathetic terminal, to release some substances which in turn results in facilitation (Levine et al., 1986; Taiwo and Levine, 1988) . Our present observations reveal that only 5-HT, and not BK or HIS, enhanced CGRP release from the rat trachea induced by CAP. These observations are in accord with other studies (see Handwerker, 1990; Lang et al., 1990 ) that indicate that 5-HT shows a more reliable sensitizing effect than other mediators, such as norepinephrine or PGE, .
The possible role of prostanoids The fact that both the effects of BK stimulation and 5-HT enhancement of CGRP release were blocked by indomethacin suggests that prostanoid production is involved in both the stimulatory and facilitatory actions on the nerve terminal. Two issues are emphasized. First, because each agent behaves differentially, that is, BK evokes release but does not sensitize while 5-HT sensitizes but does not evoke, it seems probable that different elements of the cyclooxygenase cascade must be involved in the actions of the respective agents. Second, at present it is not clear from what source the cyclooxygenase products are derived. PGs sensitize a majority of the C-polymodal afferents (Martin et al., 1987) and potentiate the vascular permeability increase induced by CAP (Saria and Lundberg, 1984) . In the preliminary study, however, no PGs examined (PGE,, PGE,, PGF,,, PGI,) showed sensitizing activity on CAP-evoked peptide release from the rat trachea, although all displayed direct excitatory effects in the same model (Hua et al., unpublished observations) . Instability of thromboxane A, prevents the investigation of the biological activity of this agent. Interestingly, a stable PGI, analog, carba-PGI,, has been reported to enhance CAP-evoked release of substance P and CGRP from rat sensory neuron (Hingtgen and Vasko, 1992) . Further work employing selective competitive receptor antagonists and stable agonists for the several prostanoids is required. In summary, the present studies have emphasized that autocoids, which are released following local injury and inflammation, are able to stimulate or sensitize the terminals of C-fibers and then evoke or facilitate the local secretion of CGRP from those terminals. The well-defined effects of CGRP during neurogenic inflammation suggest that this local activation may serve a complex role not only to provide the afferent information necessary for generating centrally mediated responses, but also to provide a local trophic regulation.
